Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
37.08
+0.56 (1.53%)
Apr 14, 2026, 12:43 PM EDT - Market open
Cogent Biosciences Stock Forecast
Stock Price Forecast
The 14 analysts that cover Cogent Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $36.21, which forecasts a -2.35% decrease in the stock price over the next year. The lowest target is $9.00 and the highest is $67.
Price Target: $36.21 (-2.35%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cogent Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Buy | 3 | 3 | 4 | 5 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 14 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $55 | Buy | Reiterates | $55 | +48.33% | Mar 17, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $55 | Strong Buy | Initiates | $55 | +48.33% | Mar 16, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $39 → $52 | Buy | Maintains | $39 → $52 | +40.24% | Feb 18, 2026 |
| Wedbush | Wedbush | Buy Reiterates $55 | Buy | Reiterates | $55 | +48.33% | Jan 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $52 | Strong Buy | Maintains | $50 → $52 | +40.24% | Jan 6, 2026 |
Financial Forecast
Revenue This Year
19.99M
Revenue Next Year
366.46M
from 19.99M
Increased by 1,733.58%
EPS This Year
-2.23
from -2.55
EPS Next Year
-0.64
from -2.23
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 44.0M | 830.2M | |||
| Avg | 20.0M | 366.5M | |||
| Low | n/a | 114.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 4,054.1% | |||
| Avg | - | 1,733.6% | |||
| Low | - | 473.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.73 | 1.64 | |||
| Avg | -2.23 | -0.64 | |||
| Low | -2.78 | -2.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.